Page last updated: 2024-11-03

proglumide and Pancreatic Neoplasms

proglumide has been researched along with Pancreatic Neoplasms in 22 studies

Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research Excerpts

ExcerptRelevanceReference
"Nude mice bearing SW-1990 pancreatic cancer xenografts were injected with CCK (5, 15, or 25 micrograms/kg) or vehicle twice daily for 20 days."5.28Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. ( Bagheri, S; Kramer, S; Smith, JP; Solomon, TE, 1990)
" Clinical symptoms and physical signs, laboratory tests, and adverse reactions were checked every 6 weeks as efficacy/tolerability criteria."2.68Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group. ( Di Prima, F; Militello, C; Pedrazzoli, S; Sperti, C, 1997)
"Pancreatic cancer is extremely resistant to various cancer therapies, however, variety of new therapies for pancreatic cancer have been investigated: (1) immunotherapy including cytokines like TNF, adoptive immunotherapy with lymphokine-activated killer cells or cytotoxic T-lymphocytes, and tumor vaccines using mutated Ki-ras oncoprotein or irradiated tumor cells which were transfected by cytokine genes; (2) gene therapy including transfer of cytokine genes or antisense Ki-ras oncogene, and a combination of gene transfer of herpes simplex virus thymidine kinase and subsequent administration of ganciclovir; (3) differentiation therapy including a quinolinone derivative, vesnarinone; (4) endocrine therapy including cholecystokinin-receptor antagonist, CR1505 or L364,718; (5) heavy water, and etc."2.40[Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others]. ( Nio, Y; Tamura, K, 1997)
"The incidence of pancreatic cancer appeared significantly (P < 0."1.29Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. ( Alaggio, R; Behboo, R; Khajeturian, E; Militello, C; Pedrazzoli, S; Perasole, A; Rovati, L; Sperti, C, 1994)
"Cholecystokinin is thought to be an important factor regulating the growth of human pancreatic cancers."1.29Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice. ( Fukumoto, M; Hayashi, H; Imamura, M; Kawabata, K; Manabe, T; Masai, Y; Morimoto, H; Nio, Y; Tsubono, M, 1993)
"Cholecystokinin and bombesin have been shown to promote pancreatic growth and development of azaserine-induced acidophilic atypical acinar cell nodules in rat pancreas after treatment for 16 weeks."1.28Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide. ( Appel, MJ; Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1992)
"Rats treated with cholecystokinin developed more acidophilic atypical acinar cell nodules, adenomas and adenocarcinomas than control animals."1.28Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats. ( Appel, MJ; Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; Sprij-Mooij, D; Van Garderen-Hoetmer, A; Woutersen, RA, 1992)
"Camostate caused an increase in growth of the pancreas and a decrease in the number of (pre)neoplastic ductular pancreatic lesions."1.28Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1991)
"Nude mice bearing SW-1990 pancreatic cancer xenografts were injected with CCK (5, 15, or 25 micrograms/kg) or vehicle twice daily for 20 days."1.28Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. ( Bagheri, S; Kramer, S; Smith, JP; Solomon, TE, 1990)
"Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats."1.28Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters. ( Jansen, JB; Lamers, CB; Meijers, M; Rovati, LC; van Garderen-Hoetmer, A; Woutersen, RA, 1990)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.55)18.7374
1990's19 (86.36)18.2507
2000's0 (0.00)29.6817
2010's2 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nadella, S1
Burks, J1
Al-Sabban, A1
Inyang, G1
Wang, J1
Tucker, RD1
Zamanis, ME1
Bukowski, W1
Shivapurkar, N1
Smith, JP3
Cooper, TK1
McGovern, CO1
Gilius, EL1
Zhong, Q1
Liao, J1
Molinolo, AA1
Gutkind, JS1
Matters, GL1
Sperti, C2
Militello, C2
Rovati, L1
Behboo, R1
Khajeturian, E1
Perasole, A1
Alaggio, R1
Pedrazzoli, S2
Nio, Y3
Tsubono, M2
Morimoto, H2
Kawabata, K2
Masai, Y2
Hayashi, H2
Manabe, T2
Imamura, M1
Fukumoto, M1
Tseng, CC1
Baba, N1
Hosokawa, Y1
Karsenty, L1
Hajri, A1
Aprahamian, M1
Garaud, JC1
Doffoël, M1
Damgé, C1
Watanapa, P1
Flaks, B1
Oztas, H1
Deprez, PH1
Calam, J1
Williamson, RC1
Tomioka, M2
Miyazaki, N2
Yamamoto, M2
Saito, Y2
Hirata, M1
Itoh, M1
Tsuchida, A1
Ooishi, H1
Hanada, K1
Kajiyama, G1
Di Prima, F1
Tamura, K1
Meijers, M5
Appel, MJ2
van Garderen-Hoetmer, A5
Lamers, CB6
Rovati, LC6
Jansen, JB6
Woutersen, RA6
Shimazoe, T1
Funakoshi, A2
Kono, A2
Sprij-Mooij, D1
Solomon, TE1
Bagheri, S1
Kramer, S1
Seva, C1
Scemama, JL1
Bastié, MJ1
Pradayrol, L1
Vaysse, N1
Douglas, BR1
de Jong, AJ1

Reviews

1 review available for proglumide and Pancreatic Neoplasms

ArticleYear
[Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others].
    Nihon Geka Gakkai zasshi, 1997, Volume: 98, Issue:7

    Topics: Animals; Benzodiazepinones; Deuterium Oxide; Devazepide; Genetic Therapy; Humans; Immunotherapy; Pan

1997

Trials

1 trial available for proglumide and Pancreatic Neoplasms

ArticleYear
Clinical evaluation and safety of loxiglumide (CCK-A receptor antagonist) in nonresectable pancreatic cancer patients. Italian Pancreatic Cancer Study Group.
    Pancreas, 1997, Volume: 14, Issue:3

    Topics: Double-Blind Method; Female; Hormone Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Lo

1997

Other Studies

20 other studies available for proglumide and Pancreatic Neoplasms

ArticleYear
Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
    American journal of physiology. Gastrointestinal and liver physiology, 2018, 11-01, Volume: 315, Issue:5

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dietary Fats; Female; Fibrosis; Male; Mice; Mice,

2018
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
    Pancreas, 2014, Volume: 43, Issue:7

    Topics: Animals; Carcinoma in Situ; Cholecystokinin; Disease Progression; Drug Screening Assays, Antitumor;

2014
Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat.
    Journal of surgical oncology, 1994, Volume: 57, Issue:1

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Body Weight; Ceruletide; Chi-Square Distr

1994
Loxiglumide (CR1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer lines xenografted into nude mice.
    Cancer, 1993, Dec-15, Volume: 72, Issue:12

    Topics: Animals; Cell Division; Chloroquine; Cholecystokinin; DNA; Esters; Gabexate; Guanidines; Humans; Mic

1993
Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer.
    Journal of surgical oncology, 1993, Volume: 53, Issue:1

    Topics: Animals; Carcinoma, Intraductal, Noninfiltrating; Cholecystokinin; DNA, Neoplasm; Dose-Response Rela

1993
Inhibition of growth of a transplanted rat pancreatic acinar carcinoma with CCK-8.
    Pancreas, 1993, Volume: 8, Issue:2

    Topics: Animals; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Neoplasm Transplantation; Pancr

1993
Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
    British journal of cancer, 1993, Volume: 67, Issue:4

    Topics: Animals; Azaserine; Biliopancreatic Diversion; Body Weight; Cholecystokinin; Cocarcinogenesis; Male;

1993
[Effect of combined use of CR1505 with UFT for the tumor growth of the subcutaneously transplanted pancreatic cancer in the Syrian golden hamsters].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1993, Volume: 90, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae;

1993
Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines.
    FEBS letters, 1996, Apr-01, Volume: 383, Issue:3

    Topics: Blotting, Western; Cell Line; Collagenases; Dose-Response Relationship, Drug; Electrophoresis, Polya

1996
Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.
    Carcinogenesis, 1992, Volume: 13, Issue:9

    Topics: Animals; Azaserine; Bombesin; Carcinogens; Cholecystokinin; Drug Synergism; Male; Pancreatic Neoplas

1992
[Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Humans; Liv

1992
[Effect of combined use of CR 1505 with UFT on tumor growth of transplanted pancreatic cancer in the Syrian golden hamster: preliminary report].
    Nihon Geka Gakkai zasshi, 1992, Volume: 93, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Cricetinae;

1992
Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.
    Gastroenterologia Japonica, 1992, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Animals; Ceruletide; Cholecystokinin; Humans; In Vitro Techniques; Liver Neoplasms;

1992
Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.
    British journal of cancer, 1992, Volume: 66, Issue:1

    Topics: Animals; Azaserine; Body Weight; Cholecystokinin; Dietary Fats; Liver; Male; Organ Size; Pancreas; P

1992
Effects of the synthetic trypsin inhibitor camostate on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
    Cancer letters, 1991, Dec-01, Volume: 60, Issue:3

    Topics: Animals; Carcinogens; Carcinoma; Carcinoma in Situ; Cholecystokinin; Cricetinae; Esters; Gabexate; G

1991
Effects of bombesin on the development of N-nitrosobis(2-oxopropyl)amine-induced pancreatic lesions in hamsters.
    Cancer letters, 1991, Jul-26, Volume: 59, Issue:1

    Topics: Animals; Body Weight; Bombesin; Cholecystokinin; Cricetinae; Liver; Male; Mesocricetus; Nitrosamines

1991
Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990.
    Digestive diseases and sciences, 1990, Volume: 35, Issue:11

    Topics: Adenocarcinoma; Animals; Cholecystokinin; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; M

1990
Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.
    Carcinogenesis, 1990, Volume: 11, Issue:12

    Topics: Animals; Body Weight; Carcinogens; Cholecystokinin; Cocarcinogenesis; Cricetinae; Male; Nitrosamines

1990
Lorglumide and loxiglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J).
    Cancer research, 1990, Sep-15, Volume: 50, Issue:18

    Topics: Animals; DNA, Neoplasm; Gastrins; Glutamine; Ornithine Decarboxylase; Pancreatic Neoplasms; Proglumi

1990
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
    Cancer research, 1989, May-01, Volume: 49, Issue:9

    Topics: Animals; Azaserine; Cholecystokinin; Esters; Gabexate; Glutamine; Guanidines; Male; Pancreatic Neopl

1989